Read up on base editing

Beam Therapeutics Appoints Financial Industry Veteran, Terry-Ann Burrell, as Chief Financial Officer

CAMBRIDGE, Mass., September 04, 2019 – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of financial industry veteran, Terry-Ann Burrell, as chief financial officer. Ms. Burrell joins Beam from J.P. Morgan, where she was a managing director in the healthcare investment banking group.

“We are thrilled to welcome Terry-Ann to the team, who brings two decades of leadership and capital markets expertise,” said John Evans, chief executive officer of Beam. “Her deep experience and track record will be invaluable to Beam as we enter a new stage of growth and expand our investment in base editing, a powerful next-generation gene editing technology that holds potential to treat patients suffering from a broad range of serious diseases.”

Ms. Burrell spent 11 years with J.P. Morgan, where she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. She was instrumental in advising clients on transaction considerations, including strategic rationale, valuation and structuring, and engaged with more than 100 companies during her tenure. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics. She holds an MBA from New York University Leonard N. Stern School of Business and a B.A. from Harvard University.

“I am overjoyed to be joining Beam and to have the opportunity to contribute to the betterment of patients’ lives,” said Ms. Burrell. “This is a special company with an exciting platform, a portfolio of programs across a range of diseases and a team of passionate individuals working toward a collective mission. I look forward to leading the finance team and collaborating with everyone at Beam to help make our mission to bring important precision genetic medicines to patients a reality.”

About Beam Therapeutics
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit www.BeamTx.com.

CONTACTS:
Media:
Katie Engleman
1AB
katie@1abmedia.com

Investors:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com